What Is the EGFR Mutation in Lung Cancer?

EGFR (epidermal growth factor receptor) is a protein on the surface of cells that regulates their growth and division. Some lung cancers have mutations in the EGFR gene. These EGFR mutations can permanently activate the receptor, sending constant growth signals that contribute to uncontrolled cancer cell growth. frontiersin+1

EGFR mutations are clinically significant because they distinguish a specific subtype of non-small cell lung cancer (NSCLC), the most common type of lung cancer. Tumours with specific EGFR mutations frequently respond positively to targeted drugs known as EGFR tyrosine kinase inhibitors (TKIs). Identifying an EGFR mutation allows the oncology team to plan treatment more precisely, aligning therapy with the tumor's biology, a key approach in precision oncology.

The NGS in Lung Cancer pillar page provides a more in-depth look at how comprehensive genomic profiling fits into patient care.

What Are the Different Types of EGFR Mutations in Lung Cancer?

EGFR mutations are not all alike. They occur in specific regions of the gene (exons), influencing how the cancer behaves and which treatments may be most effective.

Exon 19 Deletions

Exon 19 deletions remove a small stretch of DNA in the EGFR gene. This is one of the two most common EGFR mutation types in NSCLC and is strongly associated with sensitivity to EGFR-targeted therapy. Patients with exon 19 deletions often experience good responses to TKIs such as osimertinib.nature+2

L858R Mutation

The L858R mutation is a single-letter change in exon 21 that swaps one amino acid for another, leading to an overactive EGFR protein. Along with exon 19 deletions, L858R accounts for roughly 85–90% of EGFR mutations in NSCLC and is considered a “classic” or common activating mutation. It is a key marker used to guide targeted therapy decisions.onlinelibrary.wiley+2

Uncommon EGFR Mutations

Less common alterations—such as G719X (exon 18), S768I (exon 20), and L861Q (exon 21)—are collectively called uncommon or rare EGFR mutations. These can still drive cancer growth but may respond differently to treatment compared with common mutations. Some second- and third-generation TKIs (for example, afatinib or osimertinib) have shown activity against certain uncommon mutations, though responses can vary and require careful clinical interpretation.

EGFR Resistance Mutations

Over time, cancers can develop new mutations that reduce the effectiveness of targeted drugs. The best-known resistance mutation is T790M, which often emerges after first- or second-generation TKIs. Newer alterations such as C797S and other on-target or off-target changes can also drive resistance. When disease progresses on targeted treatment, resistance testing may be considered to understand what has changed and to inform next steps in lung cancer therapy.

Who Should Get EGFR Mutation Testing in Lung Cancer?

Patients with non-small cell lung cancer, particularly those with advanced or metastatic disease, should be tested for EGFR mutations. Testing determines whether a tumor contains an actionable EGFR mutation that could guide targeted therapy. mdpi+1

Factors that may influence testing decisions are

Ultimately, the treating oncology team should decide whether to test and which test to use based on guidelines, sample availability, and the clinical question at hand.

EGFR Mutation Testing for Lung Cancer

Several laboratory methods can detect EGFR mutations. The decision is based on the clinical scenario, sample type, and local laboratory capabilities.

Tissue-based EGFR Testing

This uses tumor tissue obtained through a biopsy or surgery. Tissue is the traditional gold This makes use of tumor tissue obtained through a biopsy or surgery. Tissue is the traditional gold standard that pathologists use to confirm cancer type and tumor content prior to molecular analysis. It is especially useful when a thorough examination of the tumor is required.

Liquid Biopsy and Blood-Based Testing

A liquid biopsy analyzes circulating tumor DNA (ctDNA) in a blood sample. It is useful when tissue is difficult to obtain, insufficient, or when quick results are required. A negative blood test does not always rule out an EGFR mutation, so tissue testing may still be recommended if clinical suspicion is high.

Nutritional supplements curated by oncologists

A platform for cancer nutrition.
Clinically guided. Built for care.

Shop now

NGS-based EGFR Testing

Liquid biopsy and Blood-Based Testingtypes in a single assay using next-generation sequencing (NGS). This broad perspective advances precision oncology by identifying co-occurring drivers or resistance mechanisms that may influence lung cancer treatment options. For more information on how NGS fits into care pathways, see NGS in Lung Cancer.

Other Molecular Testing Methods

Depending on the situation, laboratories may employ PCR-based assays, Sanger sequencing, or other targeted techniques. These can be useful for specific questions (for example, rapid detection of a known mutation), but they may not provide the complete genomic picture that NGS does.

EGFR testing in advanced and metastatic lung cancer.

In advanced or metastatic NSCLC, molecular testing—including EGFR—is a standard part of work-up before starting systemic therapy whenever feasible. Knowing the mutation status up front helps the team choose between targeted therapy, chemotherapy, immunotherapy, or combinations.

Repeat testing may be considered if the cancer progresses on treatment, to look for resistance mutations (such as T790M or C797S) or other changes that could open new options. However, not every patient requires repeated testing; the decision depends on treatment history, clinical status, and whether results would change management.

What Do EGFR Mutation Test Results Mean?

EGFR Mutation Positive

that the tumor may be sensitive to EGFR-targeted therapy, and the specific mutation type can help refine treatment selection.

EGFR Mutation Negative

A negative result means the tested EGFR alterations were not detected in the sample. It does not rule out other genomic drivers (such as ALK, ROS1, KRAS, MET) and does not mean no targeted options exist—just that EGFR-targeted therapy may not be the right path based on this test.

Inconclusive or Insufficient Results

Sometimes the sample does not contain enough tumor material or DNA quality is suboptimal, leading to an inconclusive result. In such cases, the oncology team may recommend repeat sampling or an alternative testing method.

Resistance-Associated Mutations

Certain mutations can emerge during treatment, influencing future planning. For example, T790M after first-line TKI or C797S after osimertinib may direct the team to different drugs or combinations. These findings necessitate careful clinical interpretation in light of prior therapy and current disease behavior.

EGFR Mutation Lung Cancer Treatment

EGFR testing alone does not treat lung cancer. Instead, it provides data to help determine whether targeted therapy is appropriate. When an actionable EGFR mutation is discovered, EGFR TKIs (such as osimertinib) can be used to inhibit the overactive growth signal that drives the tumor.

Targeted therapy differs from chemotherapy, which kills rapidly dividing cells more broadly, and immunotherapy, which activates the immune system to combat cancer. In certain situations, targeted therapy may be combined with chemotherapy or used in specific sequences to maximize benefit.

Key Takeaways About EGFR Mutation Testing